For purposes of this subpart:
The term “animal drug application” means—
section 360b(b)(1) of this title an application for approval of any new animal drug submitted under ; or
section 360ccc of this title an application for conditional approval of a new animal drug submitted under .
section 360b(b)(2) of this title Such term does not include either a new animal drug application submitted under or a supplemental animal drug application.
The term “supplemental animal drug application” means—
a request to the Secretary to approve a change in an animal drug application which has been approved; or
section 360b(c)(2) of this title a request to the Secretary to approve a change to an application approved under for which data with respect to safety or effectiveness are required.
The term “animal drug product” means each specific strength or potency of a particular active ingredient or ingredients in final dosage form marketed by a particular manufacturer or distributor, which is uniquely identified by the labeler code and product code portions of the National Drug Code, and for which an animal drug application or a supplemental animal drug application has been approved.
The term “animal drug establishment” means a foreign or domestic place of business which is at one general physical location consisting of one or more buildings all of which are within 5 miles of each other, at which one or more animal drug products are manufactured in final dosage form.
The term “investigational animal drug submission” means—
section 360b(j) of this title the filing of a claim for an investigational exemption under for a new animal drug intended to be the subject of an animal drug application or a supplemental animal drug application; or
the submission of information for the purpose of enabling the Secretary to evaluate the safety or effectiveness of an animal drug application or supplemental animal drug application in the event of their filing.
The term “animal drug sponsor” means either an applicant named in an animal drug application that has not been withdrawn by the applicant and for which approval has not been withdrawn by the Secretary, or a person who has submitted an investigational animal drug submission that has not been terminated or otherwise rendered inactive by the Secretary.
The term “final dosage form” means, with respect to an animal drug product, a finished dosage form which is approved for administration to an animal without substantial further manufacturing. Such term includes animal drug products intended for mixing in animal feeds.
The term “process for the review of animal drug applications” means the following activities of the Secretary with respect to the review of animal drug applications, supplemental animal drug applications, and investigational animal drug submissions:
The activities necessary for the review of animal drug applications, supplemental animal drug applications, and investigational animal drug submissions.
The issuance of action letters which approve animal drug applications or supplemental animal drug applications or which set forth in detail the specific deficiencies in animal drug applications, supplemental animal drug applications, or investigational animal drug submissions and, where appropriate, the actions necessary to place such applications, supplements or submissions in condition for approval.
The inspection of animal drug establishments and other facilities undertaken as part of the Secretary’s review of pending animal drug applications, supplemental animal drug applications, and investigational animal drug submissions.
Monitoring of research conducted in connection with the review of animal drug applications, supplemental animal drug applications, and investigational animal drug submissions.
The development of regulations and policy related to the review of animal drug applications, supplemental animal drug applications, and investigational animal drug submissions.
Development of standards for products subject to review.
Meetings between the agency and the animal drug sponsor.
Review of advertising and labeling prior to approval of an animal drug application or supplemental animal drug application, but not after such application has been approved.
The activities necessary for implementation of the United States and European Union Mutual Recognition Agreement for Pharmaceutical Good Manufacturing Practice Inspections, and the United States and United Kingdom Mutual Recognition Agreement Sectoral Annex for Pharmaceutical Good Manufacturing Practices, and other mutual recognition agreements, with respect to animal drug products subject to review, including implementation activities prior to and following product approval.
The term “costs of resources allocated for the process for the review of animal drug applications” means the expenses in connection with the process for the review of animal drug applications for—
officers and employees of the Food and Drug Administration, contractors of the Food and Drug Administration, advisory committees consulted with respect to the review of specific animal drug applications, supplemental animal drug applications, or investigational animal drug submissions, and costs related to such officers, employees, committees, and contractors, including costs for travel, education, and recruitment and other personnel activities;
management of information and the acquisition, maintenance, and repair of computer resources;
leasing, maintenance, renovation, and repair of facilities and acquisition, maintenance, and repair of fixtures, furniture, scientific equipment, and other necessary materials and supplies; and
section 379j–12 of this title collecting fees under and accounting for resources allocated for the review of animal drug applications, supplemental animal drug applications, and investigational animal drug submissions.
section 379g(8) of this title The term “adjustment factor” applicable to a fiscal year refers to the formula set forth in with the base or comparator month being October 2002.
The term “person” includes an affiliate thereof.
section 379g(11) of this title The term “affiliate” refers to the definition set forth in .
June 25, 1938, ch. 675, § 739Pub. L. 108–130, § 3117 Stat. 1361Pub. L. 110–85, title I, § 109121 Stat. 842Pub. L. 110–316, title I, § 102122 Stat. 3510Pub. L. 113–14, title I, § 102127 Stat. 452Pub. L. 115–234, title I, § 102132 Stat. 2428Pub. L. 118–15, div. B, title III, § 2302137 Stat. 86(, as added , , ; amended , , ; , , ; , , ; , , ; , , .)
Termination of Section
section 2307(a) of Pub. L. 118–15For termination of section by , see Termination Date note below.
Editorial Notes
Amendments
Pub. L. 118–15, § 2302(1)2023—Par. (3). , substituted “National Drug Code” for “national drug code”.
Pub. L. 118–15, § 2302(2)Par. (8)(I). , amended subpar. (I) generally. Prior to amendment, subpar. (I) read as follows: “The activities necessary for implementation of the United States and European Union Good Manufacturing Practice Mutual Inspection Agreement with respect to animal drug products subject to review, including implementation activities prior to and following product approval.”
Pub. L. 115–234, § 102(1)section 360b(b)(1) of this titlesection 360b(b)(2) of this title2018—Par. (1). , amended par. (1) generally. Prior to amendment, par. (1) read as follows: “The term ‘animal drug application’ means an application for approval of any new animal drug submitted under . Such term does not include either a new animal drug application submitted under or a supplemental animal drug application.”
Pub. L. 115–234, § 102(2)Par. (8)(I). , added subpar. (I).
Pub. L. 113–142013— amended section generally. Prior to amendment, section consisted of pars. (1) to (12) defining similar terms for this subpart.
Pub. L. 110–316, § 102(1)section 360 of this title2008—Par. (6). , substituted “that has not been withdrawn by the applicant and for which approval has not been withdrawn by the Secretary” for “, except for an approved application for which all subject products have been removed from listing under ”.
Pub. L. 110–316, § 102(2)Par. (8)(H). , substituted “but not after such application has been approved” for “but not such activities after an animal drug has been approved”.
Pub. L. 110–316, § 102(3)Par. (10). , substituted “month being October 2002” for “year being 2003”.
Pub. L. 110–316, § 102(4)Pars. (11), (12). , (5), added par. (11) and redesignated former par. (11) as (12).
Pub. L. 110–85, § 109(a)2007—, substituted “subpart” for “part” in introductory provisions.
Pub. L. 110–85, § 109(b)Par. (11). , substituted “379g(11)” for “379g(9)”.
Statutory Notes and Related Subsidiaries
Effective Date of 2023 Amendment
Pub. L. 118–15, div. B, title III, § 2306137 Stat. 89
Pub. L. 118–1521 U.S.C. 379j–11“The amendments made by this chapter [chapter 1 (§§ 2301–2307) of subtitle A of title III of div. B of , amending this section and sections 379j–12 and 379j–13 of this title and repealing provisions set out as notes under sections 379j–12 and 379j–13 of this title] shall take effect on , or the date of the enactment of this Act [], whichever is later, except that fees under part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act ( et seq.), as amended by this chapter, shall be assessed for animal drug applications and supplemental animal drug applications received on or after , regardless of the date of the enactment of this Act.”
, , , provided that:
Effective Date of 2018 Amendment
Pub. L. 115–234, title I, § 106132 Stat. 2432
section 101(a) of Pub. L. 115–234section 301 of this title21 U.S.C. 379j–11“The amendments made by this title [see , set out as a Short Title of 2018 Amendment note under ] shall take effect on , or the date of the enactment of this Act [], whichever is later, except that fees under part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act [ et seq.], as amended by this title, shall be assessed for animal drug applications and supplemental animal drug applications received on or after , regardless of the date of the enactment of this Act.”
, , , provided that:
Effective Date of 2013 Amendment
Pub. L. 113–14, title I, § 106127 Stat. 464
21 U.S.C. 379j–11“The amendments made by this title [amending this section and sections 379j–12 and 379j–13 of this title and repealing provisions set out as notes under this section] shall take effect on , or the date of enactment of this Act [], whichever is later, except that fees under part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act [ et seq.], as amended by this title, shall be assessed for all animal drug applications and supplemental animal drug applications received on or after , regardless of the date of the enactment of this Act.”
, , , provided that:
Effective and Termination Dates of 2008 Amendment
Pub. L. 110–316, title I, § 107122 Stat. 3514
section 379j–13 of this titlesection 379j–12 of this title21 U.S.C. 379j–11“The amendments made by sections 102, 103, and 104 [enacting and amending this section and ] shall take effect on , and fees under part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act [ et seq.], as amended by this title, shall be assessed for all animal drug applications and supplemental animal drug applications received on or after such date, regardless of the date of the enactment of this title [].”
, , , provided that:
Pub. L. 110–316, title I, § 108122 Stat. 3515Pub. L. 110–316section 379j–12 of this titlesection 104 of Pub. L. 110–316section 379j–13 of this titlePub. L. 113–14, title I, § 107(c)(1)127 Stat. 464, , , which provided that the amendments made by sections 102 and 103 of (amending this section and ) would cease to be effective , and that the amendment made by (enacting ) would cease to be effective , was repealed by , , .
Effective Date of 2007 Amendment
Pub. L. 110–85section 107 of Pub. L. 110–85section 379g of this titleAmendment by effective , see , set out as an Effective and Termination Dates of 2007 Amendment note under .
Termination Date
Pub. L. 118–15, div. B, title III, § 2307(a)137 Stat. 89
21 U.S.C. 379j–11“Sections 739 and 740 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. [sic] ; 379j–12) shall cease to be effective .”
, , , provided that:
Pub. L. 108–130, § 5117 Stat. 1371section 3 of Pub. L. 108–130section 4 of Pub. L. 108–130Pub. L. 113–14, title I, § 107(d)127 Stat. 464, , , which provided that the amendments made by (enacting this subpart) would not be in effect after , and that (enacting provisions set out as a note below) would not be in effect after 120 days after , was repealed by , , , effective .
Savings Provisions
Pub. L. 118–15, div. B, title III, § 2305137 Stat. 89
Pub. L. 118–1521 U.S.C. 379j–11“Notwithstanding the amendments made by this chapter [chapter 1 (§§ 2301–2307) of subtitle A of title III of div. B of , amending this section and sections 379j–12 and 379j–13 of this title and repealing provisions set out as notes under sections 379j–12 and 379j–13 of this title], part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act ( et seq.), as in effect on the day before the date of enactment of this chapter [], shall continue to be in effect with respect to animal drug applications and supplemental animal drug applications (as defined in such part as of such day) that on or after , but before , were accepted by the Food and Drug Administration for filing with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2024.”
, , , provided that:
Pub. L. 115–234, title I, § 105132 Stat. 2431
section 101(a) of Pub. L. 115–234section 301 of this title21 U.S.C. 379j–11“Notwithstanding the amendments made by this title [see , set out as a Short Title of 2018 Amendment note under ], part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act ( et seq.), as in effect on the day before the date of enactment of this title [], shall continue to be in effect with respect to animal drug applications and supplemental animal drug applications (as defined in such part as of such day) that on or after , but before , were accepted by the Food and Drug Administration for filing with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2019.”
, , , provided that:
Pub. L. 113–14, title I, § 105127 Stat. 463
21 U.S.C. 379j–11“Notwithstanding the amendments made by this title [amending this section and sections 379j–12 and 379j–13 of this title and repealing provisions set out as notes under this section], part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act ( et seq.), as in effect on the day before the date of the enactment of this title [], shall continue to be in effect with respect to animal drug applications and supplemental animal drug applications (as defined in such part as of such day) that on or after , but before , were accepted by the Food and Drug Administration for filing with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2014.”
, , , provided that:
Pub. L. 110–316, title I, § 106122 Stat. 3514
Pub. L. 108–13021 U.S.C. 379j–11section 379j–13 of this title21 U.S.C. 379j–11“Notwithstanding section 5 of the Animal Drug User Fee Act of 2003 [] ([former] note), and notwithstanding the amendments made by this title [enacting and amending this section and sections 360b and 379j–12 of this title], part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act ( et seq.), as in effect on the day before the date of the enactment of this title [], shall continue to be in effect with respect to animal drug applications and supplemental animal drug applications (as defined in such part as of such day) that on or after , but before , were accepted by the Food and Drug Administration for filing with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2009.”
, , , provided that:
Findings
Pub. L. 118–15, div. B, title III, § 2301(b)137 Stat. 86
Pub. L. 118–1521 U.S.C. 379j–11“Congress finds that the fees authorized by the amendments made in this chapter [chapter 1 (§§ 2301–2307) of subtitle A of title III of div. B of , amending this section and sections 379j–12 and 379j–13 of this title and repealing provisions set out as notes under sections 379j–12 and 379j–13 of this title] will be dedicated toward expediting the animal drug development process and the review of new and supplemental animal drug applications and investigational animal drug submissions as set forth in the goals identified for purposes of part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act ( et seq.), in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Energy and Commerce of the House of Representatives and the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate as set forth in the Congressional Record.”
, , , provided that:
Similar provisions were contained in the following prior acts:
Pub. L. 115–234, title I, § 101(b)132 Stat. 2428, , .
Pub. L. 113–14, title I, § 101(b)127 Stat. 451, , .
Accountability and Reports
Pub. L. 108–130, § 4117 Stat. 1370
Public Accountability.—
Consultation .—
21 U.S.C. 379j–11In developing recommendations to Congress for the goals and plans for meeting the goals for the process for the review of animal drug applications for the fiscal years after fiscal year 2008, and for the reauthorization of sections 739 and 740 of the Federal Food, Drug, and Cosmetic Act (as added by section 3) [, 379j–12], the Secretary of Health and Human Services (referred to in this section as the ‘Secretary’) shall consult with the Committee on Energy and Commerce of the House of Representatives, the Committee on Health, Education, Labor, and Pensions of the Senate, appropriate scientific and academic experts, veterinary professionals, representatives of consumer advocacy groups, and the regulated industry.
Recommendations .—
The Secretary shall—
publish in the Federal Register recommendations under paragraph (1), after negotiations with the regulated industry;
present the recommendations to the Committees referred to in that paragraph;
hold a meeting at which the public may comment on the recommendations; and
provide for a period of 30 days for the public to provide written comments on the recommendations.
Performance Reports .—
21 U.S.C. 379j–11Beginning with fiscal year 2004, not later than 60 days after the end of each fiscal year during which fees are collected under part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act [ et seq.], the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report concerning the progress of the Food and Drug Administration in achieving the goals identified in the letters described in section 2(3) of this Act [set out as a note above] toward expediting the animal drug development process and the review of the new and supplemental animal drug applications and investigational animal drug submissions during such fiscal year, the future plans of the Food and Drug Administration for meeting the goals, the review times for abbreviated new animal drug applications, and the administrative procedures adopted by the Food and Drug Administration to ensure that review times for abbreviated new animal drug applications are not increased from their current level due to activities under the user fee program.
Fiscal Report .—
Beginning with fiscal year 2004, not later than 120 days after the end of each fiscal year during which fees are collected under the part described in subsection (b), the Secretary shall prepare and submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on the implementation of the authority for such fees during such fiscal year and the use, by the Food and Drug Administration, of the fees collected during such fiscal year for which the report is made.”